Who registers with FDA as a human cell and tissue establishment
Any establishment that manufactures human cells, tissues, or cellular and tissue-based products (HCT/Ps) regulated solely under section 361 of the Public Health Service Act must register with FDA's Center for Biologics Evaluation and Research (CBER) and list its products under 21 CFR Part 1271. In this context, "manufacture" is broad: it covers recovering, screening, donor testing, processing, storing, labeling, packaging, and distributing HCT/Ps. That is why the registry mixes organizations that look very different from one another: organ procurement organizations that recover tissue, eye banks, bone and soft-tissue processors, cord blood banks, sperm and oocyte banks, hospital cellular therapy laboratories, donor testing laboratories, and specialist cryogenic storage and logistics providers.
Foreign establishments that import, or offer to import, HCT/Ps into the United States must register as well, and must name their U.S. agent and each known importer (21 CFR 1271.25). The public registry therefore includes cord blood banks in Spain, Turkey and India, fertility clinics in Ukraine, and tissue processors in Korea alongside U.S. sites.
The registration calendar
- Initial registration and listing: within 5 days of beginning operation.
- Annual registration: updated every December. The public record shows the "Last Annual Registration Year", which is the quickest way to spot a site that has stopped renewing.
- Changes in ownership or location, or in the U.S. agent's contact details: amended within 30 calendar days of the change.
- Product listing changes: submitted at the time of the change, or each June or December, whichever comes first.
Submissions are made electronically through eHCTERS (via CBER Online) unless FDA grants a waiver. Each registered site carries an FDA Establishment Identifier (FEI), a 10-digit number that identifies that physical location. Multi-site organizations register each location separately, so one tissue bank can appear several times under the same name with different FEIs, cities and functions.
Section 361 versus section 351 products
Only HCT/Ps that meet all four criteria of 21 CFR 1271.10(a) are regulated solely under section 361 and registered in HCTERS. The product must be minimally manipulated; intended for homologous use; not combined with another article (other than water, crystalloids, or a sterilizing, preserving or storage agent that raises no new clinical safety concern); and either have no systemic effect and not depend on the metabolic activity of living cells, or be used autologously, in a first- or second-degree blood relative, or for reproductive use. Products that fail any criterion are regulated as drugs, devices or biologics and are registered under 21 CFR Part 207 or 807 instead. A cell therapy developer can therefore hold an HCTERS registration for its collection or storage site while its finished product sits under a biologics license or an IND.
Who is exempt from registering
21 CFR 1271.15 exempts several groups, which explains why some organizations that handle tissue do not appear in the registry:
- Establishments that use HCT/Ps only for nonclinical scientific or educational purposes.
- Facilities that remove HCT/Ps from a patient and implant them back into the same patient during the same surgical procedure.
- Common carriers that accept, receive, carry or deliver HCT/Ps in the usual course of the transport business.
- Facilities that only receive or store HCT/Ps for implantation, transplantation or infusion within the same facility, without recovering, screening, testing, processing, labeling, packaging or distributing them. Many hospital operating rooms fall here.
- Establishments that only recover reproductive cells or tissue and immediately transfer them into a sexually intimate partner of the donor.
- Individuals working under contract with a registered establishment who only recover cells or tissue and send them to that establishment.
The fourth exemption matters to supply chain teams. A hospital that only stores allografts for its own surgeons generally does not register, but the moment it distributes tissue to another facility or processes it, it does.
Reading a registration record
Each public record shows the establishment's current status (Registered, Inactive or Pre-registered), FEI, address, the last annual registration year, and a grid of HCT/P types against the eight establishment functions: Recover, Screen, Donor Testing, Package, Process, Store, Label and Distribute. A separate HCT/P listing shows proprietary names where the establishment has supplied them, and satellite recovery sites point to the FEI of their parent manufacturing establishment.
The function grid is the most useful part for qualification. An establishment that only recovers bone and sends it to a processor is a different supplier from one that processes, labels and distributes finished allografts. Likewise, a cold-chain provider that lists only Store and Distribute for HPC products is a logistics partner, not a tissue source.
FDA states plainly that accepting a registration and listing does not mean the establishment complies with the regulations, or that its HCT/Ps are licensed or approved (21 CFR 1271.27(b)). Registration is a precondition for operating, not a quality endorsement. Qualification files usually pair it with accreditation from the American Association of Tissue Banks (AATB) for tissue banks, the Eye Bank Association of America (EBAA) for eye banks, or FACT or AABB for cellular therapy and cord blood programs, plus the establishment's FDA inspection history.
Registered establishments by HCT/P type
Counts of establishments with Registered status in the FDA HCTERS public query on 29 October 2026. One establishment can handle several types, so the rows overlap.
| HCT/P type | Registered establishments |
|---|---|
| Semen | 832 |
| Bone | 712 |
| Amniotic Membrane | 647 |
| Skin | 562 |
| HPC Cord Blood | 270 |
| Cornea | 228 |
| Heart Valve | 185 |
By function, the same query returned 1,954 registered establishments that store HCT/Ps, 1,847 that distribute, 1,326 that recover and 1,296 that process. There were 2,189 registered U.S. establishments and roughly 2,400 worldwide; California had 317, Texas 265, Florida 209 and New York 125.
Why a compiled view helps
The HCTERS public query returns results as paged lists, and each establishment's functions and tissue types sit on a separate detail page. Answering questions such as "which registered establishments in the Southeast process and distribute cornea" or "which cord blood banks also store umbilical cord tissue" means opening record after record. Hospital supply chain teams use this information to confirm that each allograft or cellular product supplier holds a current registration for the functions it performs. Vendors of cryogenic storage, liquid nitrogen dry shippers, temperature monitoring and biobanking software use it to see which sites recover, process or store which tissue types, and where they are located.